舒尼替尼-话题@MedSci

#舒尼替尼#

1篇内容 | 3778人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2335137, encodeId=d466233513e9b, content=<a href='/topic/show?id=d6001126303b' target=_blank style='color:#2F92EE;'>#肾细胞癌（RCC）#</a> <a href='/topic/show?id=3cc88658264' target=_blank style='color:#2F92EE;'>#舒尼替尼#</a> <a href='/topic/show?id=40c4139e9935' target=_blank style='color:#2F92EE;'>#二氢乳清酸脱氢酶（DHODH）#</a>, objectTitle=Adv Sci：南京医科大学徐爱明等团队揭示肾癌舒尼替尼耐药新机理, objectType=article, longId=941803, objectId=da7294180370, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20260610/8f31b1e4925c42e1b2ab5f0ed417f4a9-QiUmlFvcH0oW.jpg, objectUrl=/article/show_article.do?id=da7294180370, replyNumber=0, likeNumber=26, createdTime=2026-06-30, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=0, avatar=, status=0, hasArticle=1, attachment=null, ipAttribution=安徽省, moduleDTOList=null, followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2311159, encodeId=61aa231115938, content=<a href='/topic/show?id=3cc88658264' target=_blank style='color:#2F92EE;'>#舒尼替尼#</a> <a href='/topic/show?id=8cdb1044e953' target=_blank style='color:#2F92EE;'>#铜死亡#</a> <a href='/topic/show?id=d6001126303b' target=_blank style='color:#2F92EE;'>#肾细胞癌（RCC）#</a>, objectTitle=Cell子刊：武汉大学陈志远/刘修恒团队合作发现USP15蛋白助肾癌细胞“金蝉脱壳”，激活“铜死亡”成逆转耐药新武器, objectType=article, longId=937498, objectId=eef393e498b6, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20260509/6ea8b34ac2ed4ca58b6db1993eff8a68-g7S07SDxET25.jpg, objectUrl=/article/show_article.do?id=eef393e498b6, replyNumber=0, likeNumber=40, createdTime=2026-05-10, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=0, avatar=, status=0, hasArticle=1, attachment=null, ipAttribution=安徽省, moduleDTOList=null, followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2305281, encodeId=9d912305281fa, content=<a href='/topic/show?id=3cc88658264' target=_blank style='color:#2F92EE;'>#舒尼替尼#</a> <a href='/topic/show?id=a24313593315' target=_blank style='color:#2F92EE;'>#透明细胞肾细胞癌（ccRCC）#</a> <a href='/topic/show?id=4166136e425d' target=_blank style='color:#2F92EE;'>#酪氨酸激酶抑制剂（TKI）#</a>, objectTitle=Cell Death & Differ：解放军总医院张旭等团队揭示肾癌靶向药耐药新机制, objectType=article, longId=933017, objectId=077893301e97, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20260305/1f3f3ecde2f04f5099843a7af62a3880-OEpcRvVTF61y.jpg, objectUrl=/article/show_article.do?id=077893301e97, replyNumber=0, likeNumber=49, createdTime=2026-03-27, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=0, avatar=, status=0, hasArticle=1, attachment=null, ipAttribution=安徽省, moduleDTOList=null, followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2271868, encodeId=30e122e186888, content=<a href='/topic/show?id=3cc88658264' target=_blank style='color:#2F92EE;'>#舒尼替尼#</a> <a href='/topic/show?id=a7b18093982' target=_blank style='color:#2F92EE;'>#肌球蛋白#</a> <a href='/topic/show?id=103112830e2b' target=_blank style='color:#2F92EE;'>#MT-125#</a>, objectTitle=两篇Cell：“分子马达”刹车失灵？科学家有望利用实验性药物MT-125重启胶质母细胞瘤的死亡程序, objectType=article, longId=885159, objectId=24388851595c, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/bioon-com/20250702/1751459979816_1938376.png, objectUrl=/article/show_article.do?id=24388851595c, replyNumber=0, likeNumber=94, createdTime=2025-07-03, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=0, avatar=, status=0, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=null, followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2258921, encodeId=3cc722589214c, content=<a href='/topic/show?id=3cc88658264' target=_blank style='color:#2F92EE;'>#舒尼替尼#</a> <a href='/topic/show?id=a03d125e0142' target=_blank style='color:#2F92EE;'>#甲烯四氢叶酸脱氢酶2#</a>, objectTitle=Cancer Res：中山大学黄斌/陈凌武/毛晓鹏/陈俊星研究发现靶向MTHFD2有望成为克服舒尼替尼耐药性的有效策略, objectType=article, longId=869691, objectId=65a9869691d2, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20250220/1740054122286_8538692.jpg, objectUrl=/article/show_article.do?id=65a9869691d2, replyNumber=0, likeNumber=138, createdTime=2025-04-03, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=65a9869691d2, moduleTitle=Cancer Res：中山大学黄斌/陈凌武/毛晓鹏/陈俊星研究发现靶向MTHFD2有望成为克服舒尼替尼耐药性的有效策略, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=65a9869691d2)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2247067, encodeId=a9ed224e06771, content=<a href='/topic/show?id=e6c99e836f0' target=_blank style='color:#2F92EE;'>#阿昔替尼#</a> <a href='/topic/show?id=3cc88658264' target=_blank style='color:#2F92EE;'>#舒尼替尼#</a> <a href='/topic/show?id=09a6598e57a' target=_blank style='color:#2F92EE;'>#晚期肾细胞癌#</a> <a href='/topic/show?id=25e212140076' target=_blank style='color:#2F92EE;'>#阿维鲁单抗#</a>, objectTitle=Ann. Oncol | 基于 JAVELIN Renal 101 III 期试验最终分析：阿维鲁单抗+阿昔替尼与舒尼替尼作为晚期肾细胞癌一线治疗的比较, objectType=article, longId=858610, objectId=0ff08586107b, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20241101/1730425513088_8538692.jpg, objectUrl=/article/show_article.do?id=0ff08586107b, replyNumber=0, likeNumber=132, createdTime=2025-01-08, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=0ff08586107b, moduleTitle=Ann. Oncol | 基于 JAVELIN Renal 101 III 期试验最终分析：阿维鲁单抗+阿昔替尼与舒尼替尼作为晚期肾细胞癌一线治疗的比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0ff08586107b)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2186216, encodeId=37922186216fb, content=<a href='/topic/show?id=3cc88658264' target=_blank style='color:#2F92EE;'>#舒尼替尼#</a> <a href='/topic/show?id=5dd28335eea' target=_blank style='color:#2F92EE;'>#胃肠道间质瘤#</a> <a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a> <a href='/topic/show?id=594853956a' target=_blank style='color:#2F92EE;'>#ctDNA#</a> <a href='/topic/show?id=7c6e10858461' target=_blank style='color:#2F92EE;'>#瑞派替尼#</a>, objectTitle=Nat Med：胃肠道间质瘤二线治疗选瑞派替尼or舒尼替尼？血液ctDNA揭晓答案, objectType=article, longId=812546, objectId=c1938125467e, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221109/1668016299208_4754896.png, objectUrl=/article/show_article.do?id=c1938125467e, replyNumber=0, likeNumber=265, createdTime=2024-02-06, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=c1938125467e, moduleTitle=Nat Med：胃肠道间质瘤二线治疗选瑞派替尼or舒尼替尼？血液ctDNA揭晓答案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c1938125467e)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2184488, encodeId=7676218448832, content=<a href='/topic/show?id=3cc88658264' target=_blank style='color:#2F92EE;'>#舒尼替尼#</a> <a href='/topic/show?id=01a536491b9' target=_blank style='color:#2F92EE;'>#卡博替尼#</a> <a href='/topic/show?id=fc2be734870' target=_blank style='color:#2F92EE;'>#纳武利尤单抗#</a> <a href='/topic/show?id=c193110640f1' target=_blank style='color:#2F92EE;'>#ASCO GU 2024#</a>, objectTitle=ASCO GU 2024：纳武利尤单抗/卡博替尼治疗晚期肾癌优于舒尼替尼（CheckMate-9ER 研究）, objectType=article, longId=811384, objectId=440881138441, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240128/1706443016945_8624274.png, objectUrl=/article/show_article.do?id=440881138441, replyNumber=0, likeNumber=0, createdTime=2024-01-28, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=440881138441, moduleTitle=ASCO GU 2024：纳武利尤单抗/卡博替尼治疗晚期肾癌优于舒尼替尼（CheckMate-9ER 研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=440881138441)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1241273, encodeId=4a0112412e3a2, content=<a href='/topic/show?id=5dd28335eea' target=_blank style='color:#2F92EE;'>#胃肠道间质瘤#</a>与<a href='/topic/show?id=3cc88658264' target=_blank style='color:#2F92EE;'>#舒尼替尼#</a>, objectTitle=J Clin Oncol：瑞派替尼 vs 舒尼替尼后线治疗晚期胃肠道间质瘤, objectType=article, longId=735738, objectId=bcb3e35738dd, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20220812/1660287288774_2110107.JPG, objectUrl=/article/show_article.do?id=bcb3e35738dd, replyNumber=0, likeNumber=245, createdTime=2022-08-27, rootId=0, userName=循证小兵, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bcb3e35738dd, moduleTitle=J Clin Oncol：瑞派替尼 vs 舒尼替尼后线治疗晚期胃肠道间质瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bcb3e35738dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

舒尼替尼

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#肾细胞癌（RCC）# #舒尼替尼# #二氢乳清酸脱氢酶（DHODH）#

2026-06-30发表于安徽省

梅斯管理员 (审核中...)

前往app查看评论内容

#舒尼替尼# #铜死亡# #肾细胞癌（RCC）#

2026-05-10发表于安徽省

梅斯管理员 (审核中...)

前往app查看评论内容

#舒尼替尼# #透明细胞肾细胞癌（ccRCC）# #酪氨酸激酶抑制剂（TKI）#

2026-03-27发表于安徽省

梅斯管理员 (审核中...)

前往app查看评论内容

#舒尼替尼# #肌球蛋白# #MT-125#

2025-07-03发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#舒尼替尼# #甲烯四氢叶酸脱氢酶2#

Cancer Res：中山大学黄斌/陈凌武/毛晓鹏/陈俊星研究发现靶向MTHFD2有望成为克服舒尼替尼耐药性的有效策略

2025-04-03

梅斯管理员 (审核中...)

前往app查看评论内容

#阿昔替尼# #舒尼替尼# #晚期肾细胞癌# #阿维鲁单抗#

Ann. Oncol | 基于 JAVELIN Renal 101 III 期试验最终分析：阿维鲁单抗+阿昔替尼与舒尼替尼作为晚期肾细胞癌一线治疗的比较

2025-01-08发表于陕西省

梅斯管理员 (审核中...)

前往app查看评论内容

#舒尼替尼# #胃肠道间质瘤# #二线治疗# #ctDNA# #瑞派替尼#

Nat Med：胃肠道间质瘤二线治疗选瑞派替尼or舒尼替尼？血液ctDNA揭晓答案

2024-02-06发表于陕西省

梅斯管理员 (审核中...)

前往app查看评论内容

#舒尼替尼# #卡博替尼# #纳武利尤单抗# #ASCO GU 2024#

ASCO GU 2024：纳武利尤单抗/卡博替尼治疗晚期肾癌优于舒尼替尼（CheckMate-9ER 研究）

2024-01-28发表于上海

循证小兵 (审核中...)

前往app查看评论内容

#胃肠道间质瘤#与#舒尼替尼#

J Clin Oncol：瑞派替尼 vs 舒尼替尼后线治疗晚期胃肠道间质瘤

2022-08-27

科室
- - 订阅+
  - 更多科室
工具
服务